Correlation Between Jinhe Biotechnology and Contemporary Amperex

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Jinhe Biotechnology and Contemporary Amperex at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Jinhe Biotechnology and Contemporary Amperex into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Jinhe Biotechnology Co and Contemporary Amperex Technology, you can compare the effects of market volatilities on Jinhe Biotechnology and Contemporary Amperex and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Jinhe Biotechnology with a short position of Contemporary Amperex. Check out your portfolio center. Please also check ongoing floating volatility patterns of Jinhe Biotechnology and Contemporary Amperex.

Diversification Opportunities for Jinhe Biotechnology and Contemporary Amperex

0.95
  Correlation Coefficient

Almost no diversification

The 3 months correlation between Jinhe and Contemporary is 0.95. Overlapping area represents the amount of risk that can be diversified away by holding Jinhe Biotechnology Co and Contemporary Amperex Technolog in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Contemporary Amperex and Jinhe Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Jinhe Biotechnology Co are associated (or correlated) with Contemporary Amperex. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Contemporary Amperex has no effect on the direction of Jinhe Biotechnology i.e., Jinhe Biotechnology and Contemporary Amperex go up and down completely randomly.

Pair Corralation between Jinhe Biotechnology and Contemporary Amperex

Assuming the 90 days trading horizon Jinhe Biotechnology is expected to generate 1.61 times less return on investment than Contemporary Amperex. But when comparing it to its historical volatility, Jinhe Biotechnology Co is 1.94 times less risky than Contemporary Amperex. It trades about 0.19 of its potential returns per unit of risk. Contemporary Amperex Technology is currently generating about 0.15 of returns per unit of risk over similar time horizon. If you would invest  18,565  in Contemporary Amperex Technology on September 3, 2024 and sell it today you would earn a total of  7,559  from holding Contemporary Amperex Technology or generate 40.72% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Strong
Accuracy100.0%
ValuesDaily Returns

Jinhe Biotechnology Co  vs.  Contemporary Amperex Technolog

 Performance 
       Timeline  
Jinhe Biotechnology 

Risk-Adjusted Performance

14 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Jinhe Biotechnology Co are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Jinhe Biotechnology sustained solid returns over the last few months and may actually be approaching a breakup point.
Contemporary Amperex 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Contemporary Amperex Technology are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Contemporary Amperex sustained solid returns over the last few months and may actually be approaching a breakup point.

Jinhe Biotechnology and Contemporary Amperex Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Jinhe Biotechnology and Contemporary Amperex

The main advantage of trading using opposite Jinhe Biotechnology and Contemporary Amperex positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Jinhe Biotechnology position performs unexpectedly, Contemporary Amperex can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Contemporary Amperex will offset losses from the drop in Contemporary Amperex's long position.
The idea behind Jinhe Biotechnology Co and Contemporary Amperex Technology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Complementary Tools

Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years